ASCO: Results of ENHANCE 1

Abstract No : 1015

Abstract Type : Poster Discussion Session

Indication : Triple Negative Breast Cancer

Intervention : Halaven (eribulin mesylate) + Keytruda (pembrolizumab)

Company : Eisai Inc./Merck

Technology : Monoclonal antibody


As of data cutoff (July 31, 2019), 167 pts (Stratum 1, n=66; Stratum 2, n=101) were enrolled and treated. No dose-limiting toxicities were observed. The most common treatment-emergent adverse events were fatigue (66%), nausea (57%), peripheral sensory neuropathy (41%), alopecia (40%), and constipation (37%). No deaths were considered treatment related. The overall ORR was 23.4% (95% CI: 17.2–30.5). Efficacy outcomes by PD-L1 status (PD-L1+, n=74; PDL1-, n=75)


ERI + PEMBRO has activity in pts with mTNBC. There was a trend toward more robust activity for the combination among patients with PD-L1+ tumors compared to PD-L1- tumors in the first-line setting (Stratum 1); whereas, in the later-line setting (Stratum 2) similar survival outcomes were observed among the PD-L1+ and PD-L1- pts. ERI + PEMBRO shows promise for mTNBC with efficacy that appears greater than historical reports of either agent alone.


Result showed encouraging anticancer ctivity in both first line and later lines, with ORR of 25.8% and 21% respectively.

Refer to Triple Negative Breast Cancer Market report for detailed Insights.